UK MHRA Scientific Advice on Pivotal Trial of NG13-2, a Novel Product for the Prevention of Chemotherapy-Induced Alopecia Gallery UK MHRA Scientific Advice on Pivotal Trial of NG13-2, a Novel Product for the Prevention of Chemotherapy-Induced Alopecia By Jack Whitby|2025-08-07T08:27:53+00:00July 11th, 2025|News, NG13| Read More
UK MHRA Scientific Advice on Pivotal Trial of NG11-2, a Novel Product for the Prevention of Oral Mucositis Gallery UK MHRA Scientific Advice on Pivotal Trial of NG11-2, a Novel Product for the Prevention of Oral Mucositis By Jack Whitby|2025-08-07T08:28:09+00:00June 20th, 2025|News, NG11| Read More
VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme Gallery VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme By Chloe Atkinson|2024-11-13T12:56:20+00:00October 18th, 2024|Clinical Development, News, NG11| Read More
NG11-2 Phase-Ib Study Completes Last Patient Visit Gallery NG11-2 Phase-Ib Study Completes Last Patient Visit By Chloe Atkinson|2024-11-13T12:57:16+00:00August 21st, 2024|Clinical Development, News, NG11| Read More
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024 Gallery NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024 By Chloe Atkinson|2024-11-13T12:57:26+00:00July 1st, 2024|Clinical Development, News, NG11| Read More
VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference Gallery VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference By Chloe Atkinson|2025-08-05T11:07:01+00:00May 9th, 2024|Clinical Development, News, NG11| Read More
NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment Gallery NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment By Chloe Atkinson|2024-12-05T11:10:16+00:00March 4th, 2024|Clinical Development, News, NG11| Read More
VasoDynamics initiates NG13 optimisation development with key appointment Gallery VasoDynamics initiates NG13 optimisation development with key appointment By Chloe Atkinson|2024-12-05T11:09:11+00:00February 8th, 2024|Clinical Development, Corporate Development, News, NG13| Read More
NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level Gallery NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level By Chloe Atkinson|2025-02-17T12:40:59+00:00December 21st, 2023|Clinical Development, News, NG12| Read More
NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels Gallery NG11-2 Phase Ib Dose Escalation Clinical Study Progressing through Dose Levels By Chloe Atkinson|2025-05-20T09:39:47+00:00October 16th, 2023|Clinical Development, News, NG11| Read More
